Fate Therapeutics

Fate Therapeutics ($FATE) reports Q1 2026 financial results and business highlights. Read our full earnings press release for all the details: shorturl.at/NXrfl

The Fate team is presenting new data this week at the ASGCT conference in Boston – Read the details here: shorturl.at/z1DLY $FATE

We're excited to share that Fate Therapeutics has been selected for the FDA’s CDRP pilot program to support manufacturing readiness of FT819. shorturl.at/xhPZQ $FATE

The Fate team is proud to attend the ASGCT 2026 Annual Meeting, May 11–15. We look forward to connecting with the community, sharing our latest science, and advancing the conversation around transformative off-the-shelf cellular therapies. shorturl.at/syjK0 $FATE #ASGCT

We're proud to be part of the Congress of Clinical Rheumatology's East meeting this year! $FATE Press Release - shorturl.at/MJdvB

We are looking forward to participating in the Leerink Partners Healthcare Conference next week in Miami. Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9th. A link to the webcast can be found here: shorturl.at/93mIV $FATE

We’re excited to report our Q4 and FY 2025 financial results, highlighting continued progress across our clinical programs. Read the full press release here: shorturl.at/x9Xvb $FATE